Saturday Nov 21 | Daily Herald
Abbott Laboratories sued Teva Pharmaceutical Industries Ltd., the world's largest generic-drug maker, to prevent it from marketing copies of the Zemplar kidney-disease treatment.
Momenta Rises on Upgrade Ahead of Lovenox Ruling
Shares of Momenta Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying Momenta will soon receive marketing approval for its version of the anti-clotting drug Lovenox.
Israel Stocks: Israel benchmarks steady; Elbit, Formula report
Israeli stocks traded little changed Wednesday, with gains in a couple of the telecoms and scattered interest in technology stocks offset by weakness in Africa-Israel Investments, Teva Pharmaceutical Industries and Israel Chemicals.
Par Pharma gets FDA approval for generic Ultram ER
Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
Settlements and kickbacks and corporate integrity agreements, oh my To quote the BusinessWeek version of the story: A $112 million settlement involving alleged drug kickbacks that the Justice Dept.
Ratiopharm gets at least 10 bids: sources
German generic drugmaker Ratiopharm has attracted at least 10 first-round bids, several people familiar with the procedure told Reuters on Wednesday, indicating a competitive auction was underway.
The Life-and-Death Situation That Isn't
"This is literally a life-and-death issue that must be handled with great care." -- Celgene spokesman Brian Gill, as quoted in The Wall Street Journal .
Will the Israeli government prefer to protect the interests of Teva Pharmaceutical Industries or sacrifice these interests on the alter of the OECD? A document from the OECD Trade Committee reached the Ministry of Industry, Trade and Labor a few days ago; it includes questions about Israel's ideas on intellectual property.
Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
Main Category: Litigation / Medical Malpractice Also Included In: Pharma Industry / Biotech Industry Article Date: 11 Nov 2009 Teva Pharmaceutical Industries Ltd.
Teva files suit against Sandoz, Momenta over patent infringement
JERUSALEM Teva Pharmaceutical Industries has motioned to amend a complaint against two generic drug makers over their alleged infringement of Tevaa s patent on a multiple sclerosis drug.
Upgrades & Downgrades: Buying Best Buy
The route was certainly circuitous but stocks ultimately staged a modest rebound from Friday's ugly action.
Takeda sues Teva over insomnia medicine
Takeda Pharmaceutical Co., Asia's biggest drugmaker, sued Teva Pharmaceutical Industries Ltd., alleging infringement of a U.S. patent for the insomnia treatment Rozerem.
Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
Is this a rare case of Teva Pharmaceutical being forced to swallow its own bitter medicine? The world's largest generic manufacturer, founded on its unflinching willingness to challenge the patented protection of branded products owned by other drugmakers, is suing generic rival Mylan .
SchaeffersResearch.com Daily Market Blog
Option Trader Anticipates Significant Slump for Teva Pharmaceutical Industries Ltd.
Put players pounced on Teva Pharmaceutical Industries Ltd. on Tuesday, after the drug maker stepped into the earnings spotlight.
Pfizer may be eyeing deal with Israeli biotech
Pfizer Inc. is wooing up-and-coming Israeli biotech Protalix Biotherapeutics for a possible buyout or partnership, the financial newspaper TheMarker reported Monday.
Omnicare, Inc., Teva Pharmaceutical Industries Limited Unit Pay $112 Million for Kickbacks
Omnicare Inc , the largest U.S. provider of pharmacy services to nursing homes, will pay $98 million and Teva subsidiary IVAX Pharmaceuticals will pay $14 million to settle allegations of kickbacks, the U.S. Department of Justice said on Tuesday.
Teva Pharmaceutical Net Up 3%; MasterCard Sales Rises
Expeditors International of Washington, Inc , the transportation company reported third quarter revenues fell 33.3% to $1.04 billion from $1.56 billion a year ago.
Israel Stocks: Israel stocks lower; Teva reports net up 2.9%
Israeli stocks fell on Tuesday, with the benchmark index on the verge of closing below 1000 points for the first time in a month, led by weakness in telecom provider Bezeq, while Teva Pharmaceutical slipped after reporting third-quarter earnings.
Teva Pharmaceutical Q3 Sales Disappoint
Teva Pharmaceutical beat earnings expectations with its third-quarter report, although sales fell short of expectations despite a 25% increase.
StemEx(R) Noted As A Reliable Investigational Product Of An Expanded...
Main Category: Stem Cell Research Also Included In: Blood / Hematology ; Conferences Article Date: 03 Nov 2009 - 1:00 PST At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed ...
Also on Topix